Veru Inc at Jefferies Healthcare Conference Transcript
Hi, good morning. Welcome to the 2023 Jefferies Healthcare Conference. My name is Dennis Ding, biotech analyst here at Jefferies. I have the pleasure of having Veru here, and the CEO Mitch Steiner, who will give a presentation about the great progress and the outlook for the rest of the year. Mitch?
Great. Thank you. So, I'm going to tell you a little bit about our company. It's Veru, a biopharmaceutical company focused on oncology and viral ARDS. So I am going to be making some forward-looking statements, and I'd just refer you to our SEC filings and 10-K, the last one filed in 2022.
Veru is a company that has an oncology program that's focused in breast cancer. We have two Phase 3s that are planned, and I'm going to go through them in detail. The first one, that we are expecting data in a year. So late-stage clinical pipeline, using a new chemical entity called enobosarm.
And then we have a second program that's focused on the viral-induced ARDS, which
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
